PAX Stock Overview
Develops and sells Paxman scalp cooling system to minimize hair loss in connection with chemotherapy treatment worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 6/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Paxman AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 65.00 |
| 52 Week High | SEK 75.80 |
| 52 Week Low | SEK 32.00 |
| Beta | 0.78 |
| 1 Month Change | 3.83% |
| 3 Month Change | 14.04% |
| 1 Year Change | 85.71% |
| 3 Year Change | 9.06% |
| 5 Year Change | 12.07% |
| Change since IPO | 496.33% |
Recent News & Updates
Revenues Not Telling The Story For Paxman AB (publ) (STO:PAX) After Shares Rise 25%
Nov 07
Is It Time To Consider Buying Paxman AB (publ) (STO:PAX)?
Oct 22Recent updates
Revenues Not Telling The Story For Paxman AB (publ) (STO:PAX) After Shares Rise 25%
Nov 07Is It Time To Consider Buying Paxman AB (publ) (STO:PAX)?
Oct 22Results: Paxman AB (publ) Beat Earnings Expectations And Analysts Now Have New Forecasts
Aug 24Paxman (STO:PAX) Might Have The Makings Of A Multi-Bagger
Aug 07After Leaping 28% Paxman AB (publ) (STO:PAX) Shares Are Not Flying Under The Radar
Jul 18Even With A 29% Surge, Cautious Investors Are Not Rewarding Paxman AB (publ)'s (STO:PAX) Performance Completely
May 24Does Paxman (STO:PAX) Have A Healthy Balance Sheet?
Dec 23Paxman (STO:PAX) Shareholders Will Want The ROCE Trajectory To Continue
Aug 25Paxman AB (publ) (STO:PAX) Could Be Riskier Than It Looks
Jun 01Does Paxman (STO:PAX) Have A Healthy Balance Sheet?
Nov 20Is Paxman (STO:PAX) A Risky Investment?
Mar 07Paxman (STO:PAX) Is Making Moderate Use Of Debt
Mar 15Are Insiders Buying Paxman AB (publ) (STO:PAX) Stock?
Jan 22Reflecting on Paxman's (STO:PAX) Share Price Returns Over The Last Year
Dec 18
Shareholder Returns
| PAX | SE Medical Equipment | SE Market | |
|---|---|---|---|
| 7D | 3.5% | 0.4% | -2.7% |
| 1Y | 85.7% | -8.1% | 4.6% |
Return vs Industry: PAX exceeded the Swedish Medical Equipment industry which returned -7.9% over the past year.
Return vs Market: PAX exceeded the Swedish Market which returned 4.8% over the past year.
Price Volatility
| PAX volatility | |
|---|---|
| PAX Average Weekly Movement | 7.0% |
| Medical Equipment Industry Average Movement | 7.0% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in SE Market | 11.4% |
| 10% least volatile stocks in SE Market | 3.2% |
Stable Share Price: PAX has not had significant price volatility in the past 3 months compared to the Swedish market.
Volatility Over Time: PAX's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 99 | Richard Paxman | paxmanscalpcooling.com |
Paxman AB (publ), together with its subsidiaries, develops and sells Paxman scalp cooling system to minimize hair loss in connection with chemotherapy treatment worldwide. It serves various cancer centers and hospitals. The company has a research collaboration agreement with National University Hospital, Singapore for the development of portable cooling and compression device.
Paxman AB (publ) Fundamentals Summary
| PAX fundamental statistics | |
|---|---|
| Market cap | SEK 1.24b |
| Earnings (TTM) | SEK 26.28m |
| Revenue (TTM) | SEK 252.73m |
47.0x
P/E Ratio4.9x
P/S RatioIs PAX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PAX income statement (TTM) | |
|---|---|
| Revenue | SEK 252.73m |
| Cost of Revenue | SEK 82.67m |
| Gross Profit | SEK 170.06m |
| Other Expenses | SEK 143.78m |
| Earnings | SEK 26.28m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 21, 2025
| Earnings per share (EPS) | 1.38 |
| Gross Margin | 67.29% |
| Net Profit Margin | 10.40% |
| Debt/Equity Ratio | 11.8% |
How did PAX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/20 13:49 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Paxman AB (publ) is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mats Hyttinge | Redeye |